

# ASX Release

---

## SUDA ACCREDITED AS AN AUSTRALIAN TRUSTED TRADER

**PERTH, AUSTRALIA – 10 September 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has received accreditation as an Australian Trusted Trader.

The Department of Home Affairs has implemented a trade facilitation initiative: Australian Trusted Trader (ATT), delivered by the Australian Border Force. ATT recognises businesses with a secure supply chain and compliant trade practices; and rewards these accredited businesses with a range of exclusive trade facilitation benefits. This initiative will reduce regulatory burden for business and provide greater speed to market, both in Australia and overseas, through Mutual Recognition Arrangements.

Together with ISO 9001:2015 and GMP licence, SUDA demonstrates its high level of quality assurance, controls and procedures.



**Further information:**

**STEPHEN CARTER**

**EXECUTIVE CHAIRMAN**

**SUDA Pharmaceuticals Ltd**

Tel: +61 8 6142 5555

[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

**NOTES TO EDITORS:**

**About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer. For more information, visit [www.sudapharma.com](http://www.sudapharma.com).